Shares of Neurocrine Biosciences Inc. took a premarket nosedive Tuesday after the Food and Drug Administration refused to approve the highest dose of the biotech company's insomnia drug candidate.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20060516&ID=5327291)